These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12882616)

  • 41. Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease.
    Shaw J; Fishwick CW; Harris M
    Antiviral Res; 2015 May; 117():20-6. PubMed ID: 25703928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.
    Beaulieu PL
    IDrugs; 2010 Dec; 13(12):938-48. PubMed ID: 21154154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
    Deutsch M; Papatheodoridis GV
    Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent development of therapeutics for chronic HCV infection.
    Huang Z; Murray MG; Secrist JA
    Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HCV RNA-dependent RNA polymerase as a target for antiviral development.
    Walker MP; Hong Z
    Curr Opin Pharmacol; 2002 Oct; 2(5):534-40. PubMed ID: 12324255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New therapies on the horizon for hepatitis C.
    Sookoian SC
    Ann Hepatol; 2003; 2(4):164-70. PubMed ID: 15115955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
    Thompson AJ; McHutchison JG
    J Viral Hepat; 2009 Jun; 16(6):377-87. PubMed ID: 19472445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Berke JM; Vijgen L; Lachau-Durand S; Powdrill MH; Rawe S; Sjuvarsson E; Eriksson S; Götte M; Fransen E; Dehertogh P; Van den Eynde C; Leclercq L; Jonckers TH; Raboisson P; Nilsson M; Samuelsson B; Rosenquist Å; Fanning GC; Lin TI
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3812-20. PubMed ID: 21576430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
    Chatterjee A; Guedj J; Perelson AS
    Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of novel antiviral therapies for hepatitis C virus.
    Lin K
    Virol Sin; 2010 Aug; 25(4):246-66. PubMed ID: 20960299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based design of hepatitis C virus inhibitors.
    Smith RM; Wu GY
    J Viral Hepat; 2003 Nov; 10(6):405-12. PubMed ID: 14633172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Non-Nucleocide NS5B Protein Inhibitors for the Treatment of Chronic Hepatitis C Infection.
    Shan LH; Liu Y; Li YH; Liu HM; Ke Y
    Curr Top Med Chem; 2016; 16(12):1392-401. PubMed ID: 26585931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of
    Wang G; Dyatkina N; Prhavc M; Williams C; Serebryany V; Hu Y; Huang Y; Wu X; Chen T; Huang W; Rajwanshi VK; Deval J; Fung A; Jin Z; Stoycheva A; Shaw K; Gupta K; Tam Y; Jekle A; Smith DB; Beigelman L
    J Med Chem; 2020 Sep; 63(18):10380-10395. PubMed ID: 32816483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C virus and natural compounds: a new antiviral approach?
    Calland N; Dubuisson J; Rouillé Y; Séron K
    Viruses; 2012 Oct; 4(10):2197-217. PubMed ID: 23202460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New therapies on the horizon for hepatitis C: are we close?
    De Francesco R; Rice CM
    Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
    Lewis H; Cunningham M; Foster G
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.